BDXB Stock Overview
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Becton, Dickinson and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$48.92 |
| 52 Week High | US$55.45 |
| 52 Week Low | US$45.85 |
| Beta | 0.56 |
| 1 Month Change | -0.12% |
| 3 Month Change | -2.16% |
| 1 Year Change | -8.06% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| BDXB | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.8% | 2.8% | 2.9% |
| 1Y | -8.1% | -11.7% | -11.6% |
Return vs Industry: BDXB exceeded the US Medical Equipment industry which returned -11.7% over the past year.
Return vs Market: BDXB exceeded the US Market which returned -11.6% over the past year.
Price Volatility
| BDXB volatility | |
|---|---|
| BDXB Average Weekly Movement | 1.5% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BDXB is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: BDXB's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 77,000 | Tom Polen | https://www.bd.com |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
Becton, Dickinson and Company Fundamentals Summary
| BDXB fundamental statistics | |
|---|---|
| Market Cap | US$68.21b |
| Earnings (TTM) | US$1.49b |
| Revenue (TTM) | US$18.74b |
45.9x
P/E Ratio3.6x
P/S RatioIs BDXB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDXB income statement (TTM) | |
|---|---|
| Revenue | US$18.74b |
| Cost of Revenue | US$10.21b |
| Gross Profit | US$8.53b |
| Other Expenses | US$7.04b |
| Earnings | US$1.49b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.23 |
| Gross Margin | 45.51% |
| Net Profit Margin | 7.93% |
| Debt/Equity Ratio | 64.6% |
How did BDXB perform over the long term?
See historical performance and comparison